NASDAQ:GDTC CytoMed Therapeutics (GDTC) Stock Price, News & Analysis → Elon to Transform U.S. Economy? (From Porter & Company) (Ad) Free GDTC Stock Alerts $1.90 -0.16 (-7.77%) (As of 06/14/2024 ET) Add Compare Share Share Today's Range$1.90▼$2.0850-Day Range$1.90▼$2.2552-Week Range$1.90▼$9.25Volume2,134 shsAverage Volume2,799 shsMarket Capitalization$20.79 millionP/E RatioN/ADividend YieldN/APrice Target$5.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesSEC FilingsShort InterestTrends Get CytoMed Therapeutics alerts: Email Address CytoMed Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside163.2% Upside$5.00 Price TargetShort InterestHealthy0.75% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.84Based on 4 Articles This WeekInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.34 out of 5 starsMedical Sector700th out of 915 stocksPharmaceutical Preparations Industry327th out of 430 stocks 3.5 Analyst's Opinion Consensus RatingCytoMed Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageCytoMed Therapeutics has only been the subject of 1 research reports in the past 90 days.Read more about CytoMed Therapeutics' stock forecast and price target. Previous Next 4.0 Short Interest Percentage of Shares Shorted0.75% of the float of CytoMed Therapeutics has been sold short.Short Interest Ratio / Days to CoverCytoMed Therapeutics has a short interest ratio ("days to cover") of 5.8.Change versus previous monthShort interest in CytoMed Therapeutics has recently decreased by 8.31%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldCytoMed Therapeutics does not currently pay a dividend.Dividend GrowthCytoMed Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for GDTC. Previous Next 2.1 News and Social Media Coverage News SentimentCytoMed Therapeutics has a news sentiment score of 0.84. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for CytoMed Therapeutics this week, compared to 0 articles on an average week.Search InterestOnly 1 people have searched for GDTC on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, CytoMed Therapeutics insiders have not sold or bought any company stock.Percentage Held by InstitutionsOnly 0.04% of the stock of CytoMed Therapeutics is held by institutions.Read more about CytoMed Therapeutics' insider trading history. Previous Next 0.0 Earnings and Valuation Price to Book Value per Share RatioCytoMed Therapeutics has a P/B Ratio of 2.44. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about CytoMed Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto 101 MediaThe Overlooked Retirement Asset You Probably Don’t Own4 out of 5 Americans believe we’re on the brink of a retirement crisis. Luckily, in these unprecedented times, we have an unprecedented solution. Once considered a “fringe” investment, the crypto market is now taking the world by storm.Click here to access the Crypto Retirement Blueprint now. About CytoMed Therapeutics Stock (NASDAQ:GDTC)CytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers in Malaysia and Singapore. Its lead product candidate is CTM-N2D, which is in Phase I clinical trials comprising expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor to improve anti-cancer cytotoxicity. The company is also developing iPSC-gdNKT, which utilizes iPSC as a starting material to generate gdNKT, a synthetic hybrid of a gamma delta T cell and a NK cell; and CTM-GDT, a product candidate that consists of expanded gamma delta T cells and exploits the multiple recognition system of gamma delta T cell to recognize and treat a range of cancers. It has research collaboration agreement with Sengkang General Hospital Pte Ltd to establish proof-of-concept use of an injectable cartilage regeneration therapy that has been developed with donor-sourced, (allogeneic) umbilical cord-derived mesenchymal stem cells (UC-MSCs) to treat cartilage injury. The company was incorporated in 2018 and is headquartered in Singapore.Read More GDTC Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart GDTC Stock News HeadlinesJune 11, 2024 | americanbankingnews.comCytoMed Therapeutics' (GDTC) Speculative Buy Rating Reaffirmed at BenchmarkMarch 27, 2024 | morningstar.comCytoMed Therapeutics Ltd GDTCMarch 20, 2024 | finance.yahoo.comCytoMed Diversifies into Regenerative Medicine after Research Collaboration with Singapore's Sengkang General Hospital to Test Injectable Umbilical Cord-Derived Mesenchymal Stem Cells for Cartilage RegenerationMarch 18, 2024 | finanznachrichten.deCYTOMED THERAPEUTICS LIMITED: CytoMed Therapeutics to Launch Complimentary Cell Banking for Qualified Shareholders for Future Precision TherapiesMarch 18, 2024 | markets.businessinsider.comCytoMed Therapeutics to Launch Complimentary Cell Banking for Qualified Shareholders for Future Precision TherapiesMarch 18, 2024 | globenewswire.comCytoMed Therapeutics to Launch Complimentary Cell Banking for Qualified Shareholders for Future Precision TherapiesMarch 4, 2024 | globenewswire.comCytoMed Therapeutics Limited Announces Research Collaboration with Singapore Sengkang General Hospital to Advance Injectable Umbilical Cord-Derived Mesenchymal Stem Cells for Cartilage Diseases and RepairAugust 15, 2023 | finance.yahoo.comCytoMed Therapeutics Announces China Research Collaboration to Enhance its Allogeneic CAR γδ T In Vivo PersistencyAugust 8, 2023 | investing.comCytoMed Therapeutics Ltd (GDTC)August 8, 2023 | finance.yahoo.comInsiders Rewarded With S$77k Addition To Investment As CytoMed Therapeutics Stock Hits US$51mAugust 8, 2023 | finance.yahoo.comCytoMed Therapeutics Announces U.S. Patent Granted For its Licensed, Novel CAR-Gamma Delta T Cell TechnologyAugust 8, 2023 | finance.yahoo.comChinese Patent Granted for A*STAR Spinoff, CytoMed Therapeutics' Licensed Allogeneic CAR-Gamma Delta T Cell TechnologyJuly 11, 2023 | investorplace.comWhy Is CytoMed Therapeutics (GDTC) Stock Up 157% Today?See More Headlines Receive GDTC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for CytoMed Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today6/15/2024Next Earnings (Estimated)7/22/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:GDTC CUSIPN/A CIK1873093 Webw2.cytomed.sg Phone65-6250-7738FaxN/AEmployeesN/AYear FoundedN/APrice Target and Rating Average Stock Price Target$5.00 High Stock Price Target$5.00 Low Stock Price Target$5.00 Potential Upside/Downside+163.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity Ratio0.04 Current Ratio14.09 Quick Ratio14.09 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.78 per share Price / Book2.44Miscellaneous Outstanding Shares10,940,000Free FloatN/AMarket Cap$20.79 million OptionableNot Optionable Beta0.63 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesMr. Chee Kong Choo (Age 66)Executive Chairman Comp: $27.32kDr. Wee Kiat Tan Ph.D. (Age 36)CEO, COO & Director Comp: $88.13kDr. Jieming Zeng M.D. (Age 50)Ph.D., Chief Scientific & Medical Officer and Director Comp: $89.74kMs. Yvonne Goh (Age 34)Chief Financial Officer Dr. Tien Wee Luk M.D. (Age 38)Chief Clinical Officer & Director Ms. Yoong Ying Tan (Age 35)Chief Corporate Officer More ExecutivesKey CompetitorsMarinus PharmaceuticalsNASDAQ:MRNSChimerixNASDAQ:CMRXOncolytics BiotechNASDAQ:ONCYSCYNEXISNASDAQ:SCYXTiziana Life SciencesNASDAQ:TLSAView All Competitors GDTC Stock Analysis - Frequently Asked Questions Should I buy or sell CytoMed Therapeutics stock right now? 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for CytoMed Therapeutics in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" GDTC shares. View GDTC analyst ratings or view top-rated stocks. What is CytoMed Therapeutics' stock price target for 2024? 1 brokerages have issued 1-year price objectives for CytoMed Therapeutics' stock. Their GDTC share price targets range from $5.00 to $5.00. On average, they expect the company's stock price to reach $5.00 in the next year. This suggests a possible upside of 163.2% from the stock's current price. View analysts price targets for GDTC or view top-rated stocks among Wall Street analysts. How have GDTC shares performed in 2024? CytoMed Therapeutics' stock was trading at $4.90 at the beginning of 2024. Since then, GDTC stock has decreased by 61.2% and is now trading at $1.90. View the best growth stocks for 2024 here. Are investors shorting CytoMed Therapeutics? CytoMed Therapeutics saw a drop in short interest in May. As of May 31st, there was short interest totaling 35,300 shares, a drop of 8.3% from the May 15th total of 38,500 shares. Based on an average daily trading volume, of 6,100 shares, the days-to-cover ratio is currently 5.8 days. Currently, 0.8% of the shares of the stock are short sold. View CytoMed Therapeutics' Short Interest. When is CytoMed Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, July 22nd 2024. View our GDTC earnings forecast. When did CytoMed Therapeutics IPO? CytoMed Therapeutics (GDTC) raised $10 million in an initial public offering on Friday, April 14th 2023. The company issued 2,412,369 shares at a price of $4.00 per share. How do I buy shares of CytoMed Therapeutics? Shares of GDTC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:GDTC) was last updated on 6/15/2024 by MarketBeat.com Staff From Our PartnersThe #1 Crypto That You Don’t Own… YetThere’s all kinds of “signals” to follow when investing in cryptos. But there’s one signal you should pay a...Crypto 101 Media | SponsoredKiss of death from Joe BidenI did not consent. You did not consent. It’s in direct violation of the U.S. Constitution but Biden does ...Porter & Company | SponsoredTiny, One-Half Inch Pellet the Key to INFINITE Energy?It’s a tiny, $1 billion company that holds the key to this power. And yet, it’s the largest company of its ...Eagle Publishing | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | SponsoredThe Only Energy Play You Should Be Looking AtOpen AI’s Sam Altman recently helped this company raise $577 million in funding… What’s more is, It has alr...Wealthpin Pro | SponsoredBill Clinton Backing Biden Replacement???Do you want to see who I believe will be the next president of the U.S.A? It won’t be Biden…And it won’t be...The Freeport Society | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CytoMed Therapeutics Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share CytoMed Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.